Novartis AG

Open: 100.72 Close: 101.39 Change: 0.67

The 5 top things that an AI found about Novartis AG Company Inc Stock and you do not know…

The game is changing. There is a new strategy to evaluate Novartis AG fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: Novartis, AG, Chinook, Therapeutics, company, deal, Stock, …

Concept Map

Semantic Network

Stock Summary

Novartis AG researches, develops, manufactures, markets, markets healthcare products. The company operates through two segments: Innovative Medicines and Sandoz. Novarti has a license and collaboration agreement with Alnylam Pharmaceuticals.

Today's Summary

Novartis AG has entered into a $3.5 billion deal to acquire Chinook Therapeutics. Swiss drugmaker will pay $40 per share in cash to Chinooks shareholders. Share price has underperformed the FTSE Global All Cap Index by -2.02% over the past year.

Today's News

Novartis AG (NYSE:NVS) Stock Price News Toggle navigation. Home Investing Quotes Stocks United States NVSEF Overview Stock Screener Earnings Calendar. Market Data Center U.S. to be replaced. Novartis AG has entered into a $3.5 billion deal to acquire Chinook Therapeutics. The Swiss drugmaker will pay $40 per share in cash to Chinooks shareholders. Novartis will buy US-based clinical-stage biopharmaceutical company Chinook Therapeutics in a $3.5bn deal. Novartes was formed in 1996 from a merger of the two Basel pharmaceutical and chemical companies. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Chinook Therapeutics, a biopharmaceutical company, has announced that it has entered into an agreement and plan of merger with Novarti. Novartis AG is collaborating with Alnylam Pharmaceuticals to commercialize inclisiran. Chinook Therapeutics shareholders will receive $3.2 billion, or $40 per share, in cash under the agreed deal. Novartis AG is a Switzerland-based pharmaceutical company. Share price has underperformed the FTSE Global All Cap Index by -2.02% over the past year. The overall consensus recommendation for Novarts AG is Buy.

Stock Profile

"Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland."

Keywords

Are looking for the most relevant information about Novartis AG? Investor spend a lot of time searching for information to make investment decisions in Novartis AG. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: Novartis, AG, Chinook, Therapeutics, company, deal, Stock, and the most common words in the summary are: novartis, stock, market, company, ag, price, chinook, . One of the sentences in the summary was: Swiss drugmaker will pay $40 per share in cash to Chinooks shareholders. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #novartis #stock #market #company #ag #price #chinook.